

Resección cutánea con Melanoma:

Informe basado en CAP vigente, AJCC/UICC TNM 8ª ed.:

- Procedimiento: escisión. / rescisión. / biopsia de ganglio centinela. / linfadenectomía.
- Lateralidad: izquierda. / derecha. / línea media. / otros (especificar).
- Localización: piel (especificar).
- Múltiples lesiones primarias: no aplicable. / presente (indicar).
- Otras localizaciones primarias: indicar (si aplicable).
- Tipo histológico: melanoma de extensión superficial). / melanoma léntigo maligno. / melanoma spitzoide. / melanoma desmoplásico (puro / mixto). / melanoma acral. / melanoma nodular.
- Máximo espesor tumoral (Breslow): mm.
- Ulceración: no identificada. / presente, de mm de extensión.
- Niveles de infiltración: nivel I (unión dermoepidérmica) / II (focalmente dermis papilar) / III (extensamente la dermis papilar) / IV (dermis reticular) / V (tejido celular subcutáneo) de Clark.
- Grado de Mitosis: se observan X mitosis en 1mm².
- Microsatélites: no identificados. / presentes.
- Invasión linfovascular: no se observa. / presente (linfática/venosa/arterial).
- Neurotropismo: presente. / no identificado.
- Linfocitos peritumorales:
- Cambios regresivos tumorales: no identificados. / presentes.
- Márgenes quirúrgicos:
 - * Componente "in situ":
 - Margen anterior: a mm de margen teñido.
 - Margen posterior: a mm de margen teñido.
 - Margen superior / 12 h: a mm de margen teñido.
 - Margen inferior / 6 h: a mm de margen teñido.
 - Margen lateral / 9 h: a mm de margen teñido.
 - * Componente "infiltrante":
 - Margen anterior: a mm de margen teñido.
 - Margen posterior: a mm de margen teñido.
 - Margen superior / 12 h: a mm de margen teñido.
 - Margen inferior / 6 h: a mm de margen teñido.
 - Margen lateral / 9 h: a mm de margen teñido.
 - Margen medial / 3 h: a mm de margen teñido.
 - Margen profundo: a mm de margen teñido.
- Ganglios linfáticos regionales:
 - * Ganglios linfáticos aislados: .
 - * Ganglios linfáticos metastatizados: .
- Metástasis: no observadas. / presente (indicar localización).
- Otros hallazgos:
 - *
- Estudios IHQ:
 - *
 - *

Clasificación TNM (8ª edición): pT pN (/).

https://documents.cap.org/protocols/Skin.Inv_Melanoma_1.0.0.0.REL_CAPCP.pdf?_gl=1*1bueg6h*ga*MjYwNDA3MTAyLjE3MTQwMzUyNTk.*_ga_97ZFJSQQ0X*MTcxNjkxNjk0MC4xMi4wLjE3MTY5MTY5NDkuMC4wLjA

pT

pT0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma)

pT1a: Melanoma less than 0.8 mm in thickness, without ulceration

pT1b: Melanoma less than 0.8 mm in thickness with ulceration; or Melanoma 0.8 to 1.0 mm in thickness with or without ulceration

pT2a: Melanoma greater than 1.0 to 2.0 mm in thickness, without ulceration

pT2b: Melanoma greater than 1.0 to 2.0 mm in thickness, with ulceration

pT3a: Melanoma greater than 2.0 to 4.0 mm in thickness, without ulceration

pT3b: Melanoma greater than 2.0 to 4.0 mm in thickness, with ulceration

pT4a: Melanoma greater than 4.0 mm in thickness, without ulceration

pT4b: Melanoma greater than 4.0 mm in thickness, with ulceration

pN

pN0: No regional lymph node metastasis detected

pN1a: One clinically occult tumor-involved node (i.e., detected by sentinel node biopsy) with no in-transit, satellite and / or microsatellite metastases

pN1b: One clinically detected tumor-involved node with no in-transit, satellite and / or microsatellite metastases

pN1c: Presence of in-transit, satellite and / or microsatellite metastases with no regional lymph node disease

pN2a: Two to three clinically occult tumor-involved nodes (i.e., detected by sentinel node biopsy) with no in-transit, satellite and / or microsatellite metastases

pN2b: Two to three tumor-involved nodes at least one of which was clinically detected with no in-transit, satellite and / or microsatellite metastases

pN2c: One clinically occult or clinically detected tumor-involved node with presence of in-transit, satellite and / or microsatellite metastases

pN3a: Four or more clinically occult tumor-involved nodes (i.e., detected by sentinel node biopsy) with no in-transit, satellite and / or microsatellite metastases

pN3b: Four or more tumor-involved nodes, at least one of which was clinically detected, with no in-transit, satellite and / or microsatellite metastases

pN3c: Two or more clinically occult or clinically detected tumor-involved nodes with in-transit, satellite and / or microsatellite metastases and / or any number of matted nodes with in-transit, satellite and / or microsatellite metastases

pM

pM1a: Distant metastasis in skin (including subcutaneous tissues), soft tissues including muscle and / or nonregional lymph node

pM1b: Distant metastasis to lung with or without M1a sites of disease

pM1c: Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease

pM1d: Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease